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Background: Liposarcomas represent the most common histological type of soft-tissue sarcomas (STS). Its main subgroups,
WD/DD, is known to be poorly sensitive to chemotherapy, with few active agents, i.e., anthracyclines +/− ifosfamide
and trabectedin. High-dose ifosfamide (HDIFX >12 g/m2) is active in STS pts pretreated with standard-dose IFX,
though with greater toxicity. A prolonged continuous-infusion (ci) through a portable external pump may be an
alternative way to administer HDIFX.
Methods: From March 2002 to August 2013, 28 pts (median age =60, range =37–73 yrs) with advanced disease
(6 WD and 22 WD/DD) were given ciHDIFX, at the dose of 14 g/m2 as a 14-day continuous infusion every
4 weeks. Twenty-four pts (86%) were previously treated with chemotherapy (19 with anthracyclines and ifosfamide;
4 with anthracycline monotherapy; 1 with trabectedin).
Results: Seven PR (all in DDLPS), 2 minor response (MR) and 11 SD were observed. Of interest, 6 of 9 patients with PR
or MR had had SD with the previous therapy with anthracycline plus ifosfamide. The median progression-free survival
was 7 months. Most common side effects were mild myelosuppression (anemia G2-3 in 3 pts; G2-3 neutropenia in 3
pts and G4 in 1; G3 thrombocytopenia in 1 pt); nausea (G3 in 3 pts) and fatigue (G3 in 6 pts). One pts had transient G3
confusion.
Conclusions: These data suggest that ciHDIFX is active in WD/DDLPS, even in patients already treated with a
combination of anthracyclines plus ifosfamide. In this series, ciHDIFX regimen was better tolerated than HDIFX in
published studies.
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Soft tissue sarcomas represent a heterogeneous group of tu-
mours. The most common histological subtype among them
is liposarcoma, which comprises three distinct groups: well
differentiated/dedifferentiated (WD/DDLPS), myxoid/round
cell (MRCL) and pleomorphic. WD/DDLPS is the common-
est subgroup and is characterized by distinctive morphology,
genetics and natural history [1].* Correspondence: roberta.sanfilippo@istitutotumori.mi.it
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unless otherwise stated.Well-differentiated liposarcoma (WDLPS) are gener-
ally indolent tumours and typically affect people between
the ages of 40 and 60 years. They occur most frequently
in the limbs, followed by retroperitoneum, mediastinum
and head and neck region. In the retroperitoneum, WDLPS
exhibits a slow but progressive growth over many years
without metastasis, but tends to recur frequently and may
cause death due to uncontrolled local recurrences, or may
dedifferentiate and eventually acquire metastatic potential.
The risk of dedifferentiation is related to the site and is
probably around 20% in the retroperitoneum but <2% in
the limbs [2,3]. DDLPS may rarely develop as a recurrence
of a WDLPS (10% of cases) or may arise de novo typicallyral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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not necessarily) high grade [4].
WD/DDLPS have a distinctive genetic signature, as they
are characterized by the overexpression/amplification of
MDM2, HMGA2 and CDK4 which are currently regarded
as a useful diagnostic tool [5,6].
Treatment for both localized WDLPS and DDLPS is
surgery [7], while treatment options for patients with ad-
vanced disease are limited. First-line combinations of
doxorubicin and ifosfamide in advanced soft tissue
sarcoma provide response rates in the 20–40% range
[8], with outliers [9]. However, in the subgroup of WD/
DDLPS the response rate to anthracycline-based chemo-
therapy is lower and they are generally considered as a
subgroup of poorly chemosensitive soft tissue sarcomas
[10,11]. Trabectedin, approved in the European Union for
advanced STS, represents a second-line treatment for
WD/DDPLS. However, the objective response rate to this
drug does not exceed 10%, if myxoid/round cell liposar-
coma is excluded, where the drug is exceedingly active
[12]. Recently, in an effort to improve clinical outcome of
these sarcoma subtypes, several targeted therapy, such as
MDM2 antagonist or CDK4 inhibitors have been studied
[13,14], but results are preliminary and the drug develop-
ment is ongoing.
Ifosfamide is often used in the second-line chemother-
apy setting for advanced sarcoma patients, at high doses,
in the range of 12–14 g/m2 over 3–4 days. At these dose
levels, ifosfamide may be active also in patients already
exposed to standard doses in combination with doxo-
rubicin, though with greater toxicity such myelosuppres-
sion, renal toxicity, neurotoxicity, nausea and vomiting
[15-17]. Better tolerability using a continuous-infusion
regimen were reported [18,19]. The stability of ifosfa-
mide mixed with mesna within a 7-day pump [20,21],
and recently over a prolonged period of 14 days [22],
was assessed.
So, we decided to administer high dose ifosfamide in a
prolonged continuous infusion over 14 days (icHDIFX),
through two portable external pumps of 7-day duration
each. The aim of this retrospective analysis was to review
all patients with WD/DDLPS treated with ciHDIFX at our
Institution between March 2002 and August 2013.
Methods
A retrospective analysis of all advanced WD/DDLPS pa-
tients treated with ciHDIFX at Istituto Nazionale Tumori
of Milan from January 2002 to August 2013 was made.
The analysis was approved by the Institutional Ethics
Committee. Histological diagnosis was centrally reviewed
in all cases by two expert pathologists (SP and APDT). Pa-
tients with a WDLP at first diagnosis which, at the time of
their treatment with ciHDIFX, had recurred as DDLP as
documented at pathologic examination or as suggested bythe radiological imaging, are classified as patients with
DDLP. In a subgroup of DDLPS, the histological grade of
the dedifferentiated component was described according
to the FNCLCC grading system. In the subgroup of
WDLPS chemotherapy was used only in symptomatic pa-
tients, without any chance to be operated. Patients had an
Eastern Cooperative Oncology Group (ECOG) perform-
ance status (PS) of 0–3, full recovery from toxicity of
previous therapy, age >18 years, written informed consent
to treatment and data collection for research purposes.
Prior nephrectomy was allowed, and patients were
excluded only if serum creatinine level exceeded the
normal level by 2.5 times. Treatment consisted of ifosfa-
mide 14 g/m2 and mesna equidose, at a dose of 1 g/m2/
day for 14 days as follows: ifosfamide (7 g/m2) and
mesna (7 g/m2) were mixed 1:1 in normal saline (total
volume up to 275 ml) and delivered as a continuous infu-
sion via an external pump over 7 days. The pump had to
be replaced after 1 week of therapy, since no data on ifos-
famide stability beyond 7 days was available. No hydration
was required; oral hydration with 1.5 L/day was recom-
mended. When required, antiemetic prophylaxis consisted
of oral ondansetron or granisetron. Full blood count
and serum biochemistry were requested at day 1, 8 and
15. No growth factors were included in the treated
plan. The chemotherapy cycle was started again on day
28. Treatment was continued until disease progression,
unacceptable toxicity, medical decision or patient refusal.
Patient medical records were retrospectively examined
to collect clinical data. All patients were evaluated for
medical history, physical examination, full blood count
and serum biochemistry and a staging computed tomog-
raphy (CT) or magnetic resonance imaging (MRI) scan.
Patients with both local and distant recurrence were
classificated as metastatic. Tumor assessment was car-
ried out every two to three cycles. The Response Evalu-
ation Criteria in Solid Tumors (RECIST) was used to
assess response [23]. Any radiological reduction in the
sum of the longest diameters of target lesions that did
not reach the criteria for an objective partial response
(PR) was defined as a minor response (MR). The mini-
mum interval to define a stable disease (SD) was consid-
ered 8 weeks. Adverse effects were evaluated according
to the fourth version of the National Cancer Institute’s
common toxicity criteria, based on clinical and labora-
tory assessments at each cycle.
Results
Patient characteristics
Between March 2002 and August 2013, 28 patients with
locally advanced or metastatic WD/DDLPS were treated
with ciHDIFX on an outpatient basis. Their median age
was 60 years (range: 37–73). ECOG PS was 0 in 17 patients
(60%), 1 in 5 (18%), 2 in 5 (18%) and 3 in 1. Six patients
Table 1 Patients characteristics
Patients characteristics
Age, years
Median 60
Range 37–73
PS (ECOG)
0 17 (60%)
1 5 (18%)
2 5 (18%)
3 1 (4%)
Gender
Male 21 (75%)
Female 7 (25%)
Histology
Well differentiated liposarcoma 6(22%)
Well differentiated/dedifferentiated liposarcoma 22(78%)
Site of the primary tumour
Retroperitoneum 24 (85%)
Spermatic cord 3 (11%)
Mediastinum 1 (4%)
Number of prior chemotherapy regimens
0 4 (14%)
1 21 (75%)
2 3 (11%)
Prior chemotherapy (24/28 pts)
Anthracyclines + Ifosfamide (9 gr/m) 20/24 (84%)
Anthracyclines 3/24 (12%)
Trabectedin 1/24 (4%)
Table 2 Haematological toxicity (worst grade per patient)
Neutropenia N
G2-G3 3 (10%)
G4 1 (4%)
Anemia N
G2-G3 3 (10%)
G4 _
Thrombocytopenia N
G2-G3 1(4%)
G4 _
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from spermatic cord) and 22 DDLPS (19 arising from
retroperitoneum, one from mediastinum and two from
spermatic cord; locally advanced = 11; metastatic = 11).
In the subgroup of DDLPS patients, the diagnosis was
documented at pathologic examination in 20/22 cases
and suggested by the radiological imaging in 2/22 cases.
In 12 out of the 22 DDLPS patients, we were able to
analyze pathologically the dedifferentiated component.
This was scored as G3 in 11 cases and G2 in 1 case.
Seventeen patients (60%) with retroperitoneal liposarcoma
had a prior nephrectomy. Twenty-four (86%) patients
were previously treated with chemotherapy: 84% of these
patients received conventional-dose ifosfamide (9 gr/m
per cycle) associated with anthracycline as their first-line
chemotherapy. Four patients (3 DDLPS and 1 WDLP)
were treated in first line.
Twelve patients (5 WDLPS and 7 DDLPS) were subse-
quently treated with Trabectedin, with 2 SD in WDLPS
patients previously progressed to ciHDIFX and 2 PR in
WDLPS patients who achieved a SD as their best re-
sponse to ciHDIFX.
The clinical characteristics of patients are summarized
in Table 1.
Drug delivery and toxicity
A total of 105 cycles were administered, with a median
of 4 cycles per patient. (range 0–8). The starting dose
was reduced to 75% in one patient due to polycystic kid-
ney disease (creatinine value =220 μmol/L with a normal
upper value level =105.6 μmol/L). Two patients started
treatment with a creatinine value over normal level,
without any dose reduction (patients were excluded only
if serum creatinine level exceeded 2.5 × normal level)
with no documented unexpected toxicities or severe ad-
verse events.
One patient with a PS =3 stopped chemotherapy after
two days due to intestinal obstruction related to disease
progression. This patient was not evaluated for tumor
response.
Seven patients interrupted their treatment in the absence
of progression after a median of 7 cycles (range 6–8) as a
shared decision with the treating clinician, with a degree of
tumour control (PR =4, MR = 1 and SD = 2). One patients
interrupted his treatment after 5 cycles with a MR as he
underwent surgery of residual disease; other 2 patients
withdrew their consent to therapy after two and 4 cycles,
following a PR and a SD, respectively.
Two patients interrupted their treatment due to tox-
icity: one patient had a prolonged G3 thrombocytopenia
after one cycle and another had a reversible G3 confu-
sion after 2 cycles.
The haematological toxicities expressed as the lowest
value of haematological counts observed during thewhole treatment are provided in Table 2. Blood count
was normally taken on days 1, 8 and 15 of each cycle.
No febrile neutropenia was observed.
Non-haematological toxicities are reported in Table 3.
No renal failure was observed.
Table 3 Non- haematological toxicity (worst grade per
patient)
Nausea/vomiting N
G2-G3 3 (10%)
G4 _
Neurotoxicity N
G2-G3 1 (4%)
G4 _
Fatigue N
G2-G3 6 (21%)
G4 _
Renal failure N
G2-G3 _
G4 _
Figure 2 Dimensional response of the de-differentiated component,
while the well differentiated portion stable.
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Twenty-seven patients were assessed for response. Seven
patients (all with DDLPS) achieved a PR by RECIST (26%)
(Figure 1), 13 patients (9 DDLP and 4 WDLPS) had SD
(48%), with two of them (with a DDPLS) showing minor
tumor shrinkage. Overall, tumor control (PR +MR+ SD)
was >70%. According to histology, PR in the subgroup of
DDLPS was 30%.
Radiologically, all observed partial responses seemed
to affect the dedifferentiated component. Figure 2 shows
a dimensional response of the de-differentiated compo-
nent, while the well differentiated portion looked stable.
All responding patients with DDLP had a G3 dedifferen-
tiated component. One patient with a MR had a DDLP
with a G2 dedifferentiated component. All responding
patients received ciHDIFX as a second-line therapy, hav-
ing previously received standard-dose ifosfamide (9 gr/sqm)
combined with anthracyclines as their first-line. PR rate in
the subgroup of pre-treated patients was 30%.
The PFS of the whole patients group was 7.4 months.
The progression-free rate at 3 and 6 months was 63%
and 55%, respectively. Figure 3 shows the progression-
free survival curve of all patients.
According to histology, the median PFS of DDLPS was
6.2 months (Figure 4), while PFS of WDLPS was 16 months
(Figure 5).Figure 1 RECIST partial response in a DDLP.Discussion
In this series of advanced WD/DDLPS patients treated
with icHDIFX we observed an objective RECIST re-
sponse rate of 26% (30% in second/further-line patients
and 32% in those with DDLPS), with an additional 50%
of patients achieving disease stabilization. Indeed, all PR
occurred in patients with DDLPS and all of them had a
dedifferentiated high-grade component (Figures 2 and
3). All seven patients with PR and the two with MR had
been previously treated with standard-dose ifosfamide
(9 gr/sqm) associated with anthracyclines. The median
number of cycles was 4, but a subgroup of 10 respond-
ing patients interrupted their treatment in the absence
of progression after a median of 6 cycles (range 2–8).
Of interest, 6 of 9 patients with PR or MR had had SD
as their best response with the previous therapy with
anthracyclines plus standard-dose ifosfamide, and two
patients with SD had had PD as best response to the
combination.
Ifosfamide is active in soft tissue sarcomas and is usually
included in front-line multi-agent chemotherapy regi-
mens, combined with anthracyclines. Ifosfamide mono-
therapy is clinically active in advanced adult soft tissue
sarcomas: there are many phase 2 studies exploiting differ-
ent schedules of ifosfamide with a reported response rateFigure 3 Progression free survival (PFS).
Figure 4 Progression free survival (PFS) of WDLPS.
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using higher doses. Some studies showed the activity of
high doses of ifosfamide (≥12 g/sqm) even in patients
already treated with standard-dose ifosfamide in combin-
ation with anthracyclines. In our series, most patients
(75%) progressed on the combination of ifosfamide and
antracyclines. Six of 9 patients with PR or MR had a
stable disease with their previous therapy. These find-
ings provide further evidence to the capability of HDIFX
to circumvent resistance to lower doses of ifosfamide
[15-17]. Unfortunately, it is difficult to extrapolate from
these studies the response rate in the subgroup of patients
with WD/DDLPS and there are no published prospective
studies on high-dose ifosfamide selectively focusing on
WD/DDLPS.
Indeed, retrospective series reported a low chemosen-
sitivity of WD/DDLPS. In a recent retrospective series of
208 patients with advanced WD/DDLPS, the response
rate to chemotherapy with anthracycline-based regimens
was reported in 12% of patients, i.e., possibly lower than
in other sarcoma subtypes [11]. These results are in line
with another report on liposarcoma patients, whichFigure 5 Progression free survival (PFS) of DDLPS.showed only a 11% of RR in the subgroup of WD/
DDLPS, compared with 44% in myxoid/round cell lipo-
sarcomas [10]. Of course it is difficult to compare re-
sponse rates across different case series, all the more in
liposarcoma, given their heterogeneity, being often made
up of two components, a well differentiated and a dedif-
ferentiated. In any case, our data on activity of ciHDIFX
in WD/DDPLS compare favourably with published evi-
dence. Of interest, in terms of response rate, ciHDIFX
looks active in the subgroup of DDLPS, especially with a
high-grade dedifferentiation. Also the higher response rate
in the subgroup of patients treated in second/further line
may be related to the presence of a WDLP between the 4
patients treated in first line. Progression-free survival was
higher in the subgroup of WDLPS patients, but, of course,
this reflects the slower growth rate associated with this
histology. Radiologically, the well differentiated and the
dedifferentiated components can be appreciated, since the
former has the characteristics of the adipose tissue, while
the latter is more dense. However, the recognition of the
two components may be flawed by the fact that some well
differentiated tumors, i.e. sclerosing and/or inflammatory,
may look dense. Figure 2 exemplifies the differential re-
sponse of an obvious well differentiated component and
the dedifferentiated.
The main problem of high-dose ifosfamide given as a
3-day infusion is tolerability, as the studies performed
showed myelosuppression, renal toxicity, and neurotox-
icity [15,16,18] In this sense, a prolonged 14-day con-
tinuous infusion of high-dose ifosfamide looks much
better tolerated. Though our toxicity data are limited by
the availability of blood count and serum biochemistry
only at day 1, 8 and 15, no febrile neutropenia was re-
ported and no growth factors were used in our series.
No renal failure was reported, even in the subgroup of
patients who had prior nephrectomy as part of their
treatment for the primary tumour.
Of interest, in the subgroup of 12 patients treated with
Trabectedin after progression to ciHDIFX we observed 2
SD and 2 PR in WDLPS patients who had obtained PD
and SD, respectively, with ciHDIFX. This suggests the
hypothesis that trabectedin might have a different activ-
ity profile, being possibly more active in the subgroup of
patients with WDLPS who respond less to ifosfamide,
and vice versa. If confirmed, this could help personalize
treatment choices on the basis of the histology and/or
the radiological aspect of the ongoing relapse.
In conclusion, our data suggest that icHDIFX is a valid
option for patients with advanced WD/DDLP even if
already treated with a combination of anthracyclines and
ifosfamide. The activity seems to be higher in those pa-
tients with a high-grade dedifferentiated component,
and represents a good compromise between activity and
tolerability. As this is a small size retrospective series,
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validate these observations. A randomized prospective
EORTC study on high-dose ifosfamide versus cabazitaxel
will now be set up to confirm these data prospectively.
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